Location:
Kardinal Wendel Haus
Mandlstrasse 23, 80802 Munich

Day 3: THURSDAY, 17th

09:00 – 09:45  Plenary Speech

               Genetics of Small Vessel Disease: Discovery, Biology, and Clinical Applications

               Martin Dichgans, LMU Hospital, Institute for Stroke and Dementia Research, Munich,                  Germany

09:45 – 10:20  Selected Oral Abstracts (10 min + 2 min each)

               TBD

               TBD

               TBD

10:20 – 10:50  Coffee break

10:50 – 12:30  Session 7 – ICAAA Guidelines for CAA (each talk 20 + 5 min)

               Chair: Steve Greenberg, Massachusetts General Hospital / Harvard Medical School,                    Boston, USA

10:50 – 11:15   Diagnosis, testing, and risk prediction

                Eric Smith, University of Calgary, Alberta, Canada

11:15 – 11:40   Treatments/interventions: use of antithrombotic agents

                Karin Klijn, Radboud University, Nijmegen, NL

11:40 – 12:05   Treatments/interventions: blood pressure, other medications, lifestyle

                Charlotte Cordonnier, Lille University Hospital, France

12:05 – 12:30   Diagnosis and treatment of CAA-ri

                David Werring, University College London, UK

12:30 – 14:00   Lunch & Poster viewing

14:00 – 15:30   Session 8: What are the next intervention trials for CAA? (each talk 20 + 5 min)

                Chair: Mark van Buchem, Leiden University Medical Center, NL

14:00 – 14:25   Interventions targeting APP expression

                Neal Parikh, Alnylam Pharmaceuticals

14:25 – 14:50   Medin as a treatment target in CAA and AD

                Jonas Neher, DZNE, Munich, Germany

14:50 – 15:15   Interventions targeting vessel remodeling/inflammation

                Marieke Wermer, Leiden University, NL

15:15 – 15:45   ICAAA organisation update & Official Conference Closure

                Steven Greenberg, ICAA Association